UC Health one of three sites in Ohio to provide new Alzheimerâs treatment Share Updated: 11:22 AM EDT Jun 9, 2021 WLWT Digital Staff Share Updated: 11:22 AM EDT Jun 9, 2021
Hide Transcript
Show Transcript REPORTER: SOME ARE CALLING THIS AIG B SPTE FORRDWA IT DOES COME WITH CONTROVERSY. A CONTROVERSIAL ALZHEIMER S TREAENTTM FROM CAMBRIDGE BASED BIOGEN GETTING THE FDA STAMP OF APPROVAL. IT S THE FIRST DRUG OF ITS KIN BACKED BY THE FDA TO TREAT THE ACTUAL UNDERLYING DISEASE, AND NOT JUST SYTO.MP IT S A VERY IMPORTANT FIRST STEP IN THE TREATMENT OF ZHEIALMER S DEASEIS THE TATREMENT HAD NOT BEEN SWNHO TO HELP. THEY SAW GOOD RESULT FOR PEOPLE IN THE EARLY STAGES. THIS IS FOR PEOPLE WHO HAVE ATWH WE CALL MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER S DISEASE OR VERY MILD DISEASE. REPORTER: BIOGEN CEO SAYS THIS HISTORIC MOMENTHE T CULMINATION OF GROUNDBREINAK RESEARCH. MEDICINE WILL TRANSFORM THE TREATMENT OF PEOPLE LIVING WITH ALZHEI
UC Health to offer just-approved Alzheimer s treatment Terry DeMio, Cincinnati Enquirer
UC Health will be among three sites in Ohio to administer the first medication to target an underlying cause of Alzheimer s disease and the first that s been approved for use in nearly two decades.
The Food and Drug Administration approved aducanumab, produced by Biogen, Inc., and to be marketed under the name Aduhelm on Monday, and UC Health, announced its role in treatment ion Wednesday. The drug is expected to be available to patients later this year, officials said.
Aducanumab is administered through monthly intravenous infusions at specialty infusion centers such as UC Health.
UC Health one of three sites in Ohio to administer Biogen s Alzheimer s drug bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.